Skip to main content

Find Clinical Trials

Home
Conditions
Myelodysplastic Syndromes

Clinical trial condition

Myelodysplastic Syndromes

Explore clinical trials studying Myelodysplastic Syndromes. Study availability and eligibility vary by location and protocol.

1,362 public trials 239 recruiting studies

Refine in advanced search Browse all conditions

Myelodysplastic Syndromes trial results

Completed

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations: Univ of Alabama Birmingham Birmingham, Alabama, United States

Mayo Clinic Phoenix, Arizona, United States

Bay Area Cancer Research Group Concord, California, United States

City of Hope National Medical Center Duarte, California, United States

View all 48 locations

View Trial Details

Completed

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

NCT00003816

Conditions: Anemia, Anemia, Aplastic, Anemia, Refractory, +90 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Completed

TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

NCT03397173

Conditions: Acute Myeloid Leukemia, Bone Marrow Diseases, Hematologic Diseases, +9 more
Locations: Cleveland Clinic, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

NCT01020539

Conditions: Acute Myelogenous Leukemia, Bone Marrow Diseases, Hematologic Diseases, +11 more
Locations: Columbia University Medical Center New York, United States

View Trial Details

Completed

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

NCT01953692

Conditions: Blood Protein Disorders, Bone Marrow Diseases, Cardiovascular Diseases, +27 more
Locations: Not specified

View Trial Details

Completed

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

NCT01221857

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Bone Marrow Diseases, +22 more
Locations: Loyola University, Cardinal Bernardin Cancer Center Maywood, Illinois, United States

Duke University Medical Center Durham, North Carolina, United States

View Trial Details

Completed

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

NCT03555955

Conditions: Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, +18 more
Locations: Georgetown University Medical Center Washington D.C., District of Columbia, United States

Northside Hospital - Blood and Bone Marrow Transplant Group of Georgia Atlanta, Georgia, United States

University of Kansas Cancer Center Westwood, Kansas, United States

Hackensack University Medical Center Hackensack, New Jersey, United States

View all 13 locations

View Trial Details

Completed

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

NCT00488592

Conditions: Acute Myeloid Leukemia (AML), Bone Marrow Diseases, Chronic Disease, +15 more
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States

View Trial Details

Completed

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

NCT01690520

Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, +22 more
Locations: City of Hope Comprehensive Cancer Center Duarte, California, United States

Stanford Cancer Institute Palo Alto Palo Alto, California, United States

University of Colorado Denver, Colorado, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

NCT01822509

Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blood Protein Disorders, Bone Marrow Diseases, +44 more
Locations: City of Hope Comprehensive Cancer Center Duarte, California, United States

UC San Diego Moores Cancer Center La Jolla, California, United States

City of Hope South Pasadena South Pasadena, California, United States

Colorado Blood Cancer Institute Denver, Colorado, United States

View all 13 locations

View Trial Details